Purple Biotech Ltd. released preclinical data at the EACR 2026 conference regarding its IM1240 candidate. The data highlighted the compound's anti-tumor activity, favorable safety profile, pharmacokinetic profile, and broad therapeutic window. Purple Biotech is a biotechnology company focused on drug development.
